drugset / Trial / NCT00038623
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed \& Refractory Mantle Cell Lymphoma
Timeline
- Start
- 2002-04
- Primary completion
- 2007-12
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | — | Intravenous |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |